FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2018/05/014122 [Registered on: 25/05/2018] Trial Registered Retrospectively
Last Modified On: 22/05/2019
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Ayurveda 
Study Design  Single Arm Study 
Public Title of Study   Clinical study of Hair Oil formulation in Hair loss in females. 
Scientific Title of Study   An Open Label, Single arm, Prospective Clinical Study to evaluate efficacy and safety of Hair Oil formulation in mild to moderate Hair loss in females. 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
EM/HO-01/2017, Version 1.0, Dated 31st Oct 2017  Protocol Number 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Maheshkumar Harit  
Designation  Principal  
Affiliation  D. Y. Patil University School of Ayurveda Nerul Navi, Mumbai 
Address  OPD No. 1 Ground Floor, Department of Kayachiktsa D. Y. Patil University School of Ayurveda Nerul Navi, Mumbai MAHARASHTRA

Mumbai (Suburban)
MAHARASHTRA
400706
India 
Phone  9322217607  
Fax    
Email  drmaheshkharit@rediffmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Sanjay Tamoli 
Designation  Director 
Affiliation  Target Institute of Medical Education and Research 
Address  Target Institute of Medical Education and Research 205, B Wing, Blue Diamond Society, Nayagoan, Dahisar West, Mumbai

Mumbai (Suburban)
MAHARASHTRA
400068
India 
Phone  9322522252  
Fax    
Email  targetinstitute@yahoo.com  
 
Details of Contact Person
Public Query
 
Name  Vandana Bade 
Designation  Manager - Clinical Trial Operation 
Affiliation  Target Institute of Medical Education and Research 
Address  Target Institute of Medical Education and Research 205, B Wing, Blue Diamond Society, Nayagoan, Dahisar West, Mumbai

Mumbai (Suburban)
MAHARASHTRA
400068
India 
Phone  8149507065  
Fax    
Email  vandana@targetinstitute.in  
 
Source of Monetary or Material Support  
Emami Ltd, Express Zone, Western Express Highway, Goregaon West, Mumbai-400065  
 
Primary Sponsor  
Name  Emami Ltd 
Address  Express Zone, Western Express Highway, Goregaon West, Mumbai-400065  
Type of Sponsor  Pharmaceutical industry-Indian 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Maheshkumar Harit   D. Y. Patil University School of Ayurveda Nerul Navi Mumbai   OPD No. 1 Ground Floor, Department of Kayachiktsa D. Y. Patil University School of Ayurveda Nerul Navi Mumbai 400706 MAHARASHTRA
Mumbai (Suburban)
MAHARASHTRA 
9322217607

drmaheshkharit@rediffmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethics Committee, D. Y. Patil University, School of Ayurveda, Nerul, Navi Mumbai  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  Mild to moderate Hair loss in females,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  EM/HO-01  Dosage and Treatment Duration: 5 to 10 ml hair oil daily on the scalp with fingertips before going to bed at night or before bath for 60 days 
Comparator Agent  NIL  NIL 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  45.00 Year(s)
Gender  Female 
Details  1.Female subjects between the age group of 18- 45 years both inclusive.
2.Subjects suffering from mild to moderate hair loss (40-140 Hair by Comb test and Finger Test).
3.Subjects who are infrequent hair oil users.
4.Subjects who are willing to give informed consent and ready to comply with the protocol.
5.Subjects who are ready to provide regular follow ups till the completion of the study.
 
 
ExclusionCriteria 
Details  1.Subjects with severe Hair fall due to any clinically significant disorder/s like anemia, thyroid disorders etc.
2.Subject with severe dermatological disorders of the scalp that might interfere with the study evaluation.
3.Subjects with recent disease history like malaria, typhoid, jaundice and scalp diseases and subjects who in the opinion of the investigator are not eligible for enrollment in the clinical study.
4.Subjects who have regularly used anti-hair fall treatment with hair oil over the last 6 months.
5.Subjects who have previously undergone hair transplantation procedures.
6.Subjects on systemic steroids for more than 14 days within 2 months prior to enrollment.
7.Subjects on immunosuppressive drugs.
8.Known cases of Hypersensitivity to hair oil contents.
9.Subjects who have participated in any other clinical study since last 3 months.
10.Subjects who are reported pregnant/planning a pregnancy or lactating.
11.Menopausal Women.
 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
1. Assessment of hair fall by running finger test over a period of 60 days.
2. Assessment of hair breakage by comb test over a period of 60 days
 
Day -3, Day 0, Day 15, Day 30, Day 45, Day 60 
 
Secondary Outcome  
Outcome  TimePoints 
1.Assessments of hair fall by Hair Pull test.
2.Assessment of hair growth by comparing against standard nonusers.
3.Assessment of effect of hair oil on dandruff in females by standard dandruff evaluation strip.
4.Assessment of effect of hair oil on quality of hair based on subject questionnaire.
5.Global assessment for overall change in hair loss by the physician and subject.
6.Assessment of safety by observing episodes, severity and duration of any allergic reactions and adverse events.
 
Day -3, Day 0, Day 15, Day 30, Day 45, Day 60 
 
Target Sample Size   Total Sample Size="50"
Sample Size from India="50" 
Final Enrollment numbers achieved (Total)= "50"
Final Enrollment numbers achieved (India)="50" 
Phase of Trial   Phase 2/ Phase 3 
Date of First Enrollment (India)   18/12/2017 
Date of Study Completion (India) 20/02/2018 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Date Missing 
Estimated Duration of Trial   Years="0"
Months="10"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  
Not Applicable 
Recruitment Status of Trial (India)  Completed 
Publication Details   Not Yet Done 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Brief Summary
Modification(s)  

Brief Methodology:

It is an open label, single arm, prospective clinical study to evaluate efficacy and safety of Hair Oil formulation in mild to moderate Hair loss in females. The study will be conducted at one site in India. Subjects will be advised to apply 5 to 10 ml hair oil daily on the scalp with fingertips before going to bed at night or before bath for 60 days. The Primary objectives of study will be assessment of hair fall by running finger test and assessment of hair breakage by comb test over a period of 60 days. The Secondary objectives of study will be assessments of hair fall by Hair Pull test, assessment of hair growth by comparing against standard nonusers, assessment of effect of hair oil on dandruff in females by standard dandruff evaluation strip, assessment of effect of hair oil on quality of hair based on subject questionnaire, global assessment for overall change in hair loss by the physician and subject, and assessment of safety by observing episodes, severity and duration of any allergic reactions and adverse events.

Results:

A). Primary Objectives:

1)   Assessment of hair fall  reduction by running finger test over a period of 2 months:

There is a significant reduction in hair fall as analyzed by Running Finger test from baseline to 15 days, which continued till the end of the study. The average hair fall at the baseline visit was 79.35 ±28.54, which significantly reduced to 53.60 ±32.05 at the end of 15 days. At the end of 30 days the hair fall further reduced to 41.42 ±27.19 while at the end of 45 days it was observed to be 37.36 ±25.94. At the end of 60 days the average hair fall was seen to be 34.36 ±32.72, which was significant as compared to its baseline reading. It was also observed that there was a 47.8% reduction in hair fall at the end of one month while at the end of 60 days the average hair fall reduced by 56.69%.

2)   Assessment of hair breakage by comb test over a period of 2 months:

The average no of hair as per comb test were 16.04 ±13.16 at the baseline visit. This reduced to 11.04 ±9.55 and 9.36 ±10.18 at the end of 15 days and 30 days respectively, which was found to be statistically significant. At the end of 45 days and 60 days the counts were 8.13 ±9.71 and 8.55 ±8.94 respectively. These reductions were found to be significant as compared to the baseline. There was a 41.64% reduction in hair count by comb test at the end of 30 days, which further improved to 46.7% at the end of 60 days.

B). Secondary Outcome:

1). Assessment of hair fall  by Hair Pull test over a period of 2 months

The average no of hair fall as per pull test were 1.64 ±1.68 at the baseline visit. This reduced to 1.04 ±1.20 and 0.76 ±1.09 at the end of 15 days and 30 days respectively, which was found to be statistically significant. At the end of 45 days and 60 days the counts were 0.82 ±1.33 and 0.78 ±1.49 respectively. These reductions were found to be significant as compared to the baseline. There was a 53.85% reduction in hair fall by pull test at the end of 30 days which further improved to 52.75% at the end of 60 days.

2). Assessment of effect of EM/HO-01 hair oils on dandruff in females by standard dandruff evaluation strip.

The Dandruff score was 1.75 ±1.27 at the baseline visit. This reduced to 1.38 ±1.16 and 1.47 ±1.39 at the end of day 15 and day 30 respectively which was found to be statistically significant. This continued further at 45 days and 60 days where the score were 1.31 ±1.44 and 0.95 ±1.10 respectively. These reductions were found to be statistically significant. The percentage reduction in Dandruff score was found to be 20.83 % at the end of 15 days, 15.62% at day 30, 25 % at day 45 and 45.83 % at day 60 as compared to the baseline.

3). Assessment of effect on quality of hair based on subject questionnaire.

a)   a). Assessment of effect on Visibility of scalp, Smoothness of Hair, Thickness of Hair.

The visibility of scalp as evaluated on VAS. It is observed that at day 30, subjects had an average score of 0.94 ±1.06 (improvement), while the end of 60 days the score was 1.70 ±1.10. This change was found to be statistically significant between these two visits.

Smoothness was evaluated on VAS scale by the subject on Day 30 and day 60. It is observed that the average smoothness was found to be 2.14 ±0.64, while it was 2.78 ±1.06 at the end of 60 days. The difference between day 30 and day 60 was found to be statistically significant.

Thickness of hair was evaluated on VAS scale by the subject on Day 30 and day 60. It was observed that the average thickness was found to be 1.62 ±0.85 in EM/HO-01 group. Thickness showed a further increase of average to 2.30 ±1.13 at the end of day 60.

b). Assessment of effect on hair growth

It is observed that 6% of subjects showed mild worsening of their condition of hair fall at Day 30. On day 60 this percentage was observed as 8%. It was also observed that 24% had no change at day 30 and 6% were recorded to have no change on day 60. 72% and 86% of subjects reported of Slight to moderate improvement in their condition at Day 30 and Day 60 respectively.

c). Assessment of effect on appearance of hair:

It is observed that 6% of subjects showed mild worsening of their condition of hair fall at Day 30. On day 60 this percentage was observed as 8%. Of these 24% had no change at day 30 and 6% were recorded to have no change on day 60. It was observed that 72% and 86% of subjects reported of Slight to Moderate improvement in their condition at Day 30 and Day 60 respectively.

d)   Assessment of effect in slowing down hair loss:

It is observed that 6% of subjects showed either severe or moderate or mild worsening of their condition of hair fall at Day 30. On day 60 this percentage was observed as 8%. In the study it was observed that 30% had no change at day 30 and 20% were recorded to have no change on day 60. 64% and 72% of subjects reported of Slight to Marked improvement in their condition at Day 30 and Day 60 respectively.

 e)   Assessment of effect on greying of hair:

It is observed that all the subjects showed no change in their greying of hair at day 30 while at day 60, 98% of the subjects showed no change while 2% subjects showed slight improvement.

4) Global assessment of Overall Change in hair loss by the Physician:

Physicians Global improvement scale (CGI-I) showed that 82% of the subjects were very much improved, much improved or minimally improved. 10% of subjects did not have any change while 8% subjects were minimally to much worse. 

5) Global assessment of Overall Change in hair loss by Subject:

Subject’s Global improvement scale (CGI-I) showed that 82% of the subjects were very much improved, much improved or minimally improved. 10% of subjects did not have any change while 8% subjects were minimally to much worse.

6) Assessment of Overall Safety as per the Physician:

It is observed that 90% of the subjects had excellent overall safety while 10% had good overall safety. Assessment of adverse events showed apart from a few subjects complaining of itching in the scalp none of the adverse events were related to the study product. Assessment of vitals like pulse, temperature and respiratory rate also observed that there were no significant changes on these parameters over the period of 60 days of study in both the groups.

7) Assessment of safety by observing episodes, severity and duration of any allergic reactions & adverse events:

There were total few adverse events (AEs) such as cough, facial palsy, nausea, insomnia, burning throat, loose motion, vomiting and hyperacidity during the trial. Among this no AEs were related to the study Product.

Conclusion:

It can be concluded from the study that there was a significant reduction in hair fall as assessed by running finger test. Assessment by comb test for hair breakage observed that there was a significant reduction at the end of 60 days of study. Assessment on other parameters also showed significant improvement in the quality of hair, dandruff etc.

Assessment of safety showed that all the subjects showed excellent to good safety with only a few subjects having mild episodes of itching of the scalp.

 


 
Close